Background: Considerable studies showed associations between chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD), we evaluated the role of endogenous hydrogen sulfide (H(2)S)/homocysteine (Hcy) in patients with COPD combined with CVD. Methods: Fifty one stable patients with COPD were enrolled (25 COPD, 26 COPD + CVD). Lung function, sputum, peripheral blood samples, serum H(2)S, Hcy, high-sensitivity C-reactive protein (hs-CRP) and tumor necrosis factor-α (TNF-α) levels were measured. Dyspnea, symptoms and quality of life were quantified by modified Medical Research Council dyspnea scale (mMRC), COPD assessment test (CAT) and St. George's Respiratory Questionnaire (SGRQ). Results: Compared with COPD group, waist circumference and body mass index (BMI) were higher in COPD + CVD group, mMRC, CAT and activity scores were also higher, high density lipoprotein cholesterol (HDL-C) was lower, total cells, neutrophils (%) in sputum and serum hs-CRP level were higher, whereas macrophages (% ) in sputum was lower. H(2)S and Hcy levels from COPD + CVD group were higher than those from COPD group, but H(2)S/Hcy ratio was lower. With increasing COPD severity, H(2)S level was decreased, however, Hcy level was increased. H(2)S level was positively correlated with FEV(1)/FVC, FEV(1)% predicted, lymphocytes (%) and macrophages (%) in sputum, but negatively correlated with smoking pack-years and neutrophils (%) in sputum. Hcy level was positively correlated with BMI and total cells in sputum. The ratio of H(2)S/Hcy was also positively correlated with FEV(1)/FVC, but negatively correlated with total cells in sputum. Conclusion: The imbalance of H(2)S/Hcy may be involved in the pathogenesis of COPD combined with CVD and provide novel targets for therapy.
Imbalance of Endogenous Hydrogen Sulfide and Homocysteine in Chronic Obstructive Pulmonary Disease Combined with Cardiovascular Disease.
慢性阻塞性肺病合并心血管疾病中内源性硫化氢和同型半胱氨酸失衡
阅读:9
作者:He Yanjing, Liu Shaoyu, Zhang Zhe, Liao Chengcheng, Lin Fan, Yao Wanzhen, Chen Yahong
| 期刊: | Frontiers in Pharmacology | 影响因子: | 4.800 |
| 时间: | 2017 | 起止号: | 2017 Sep 12; 8:624 |
| doi: | 10.3389/fphar.2017.00624 | 研究方向: | 心血管 |
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
